

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61L 25/00, A61K 35/54	A1	(11) International Publication Number: WO 94/02182 (43) International Publication Date: 3 February 1994 (03.02.94)
(21) International Application Number: PCT/EP93/01797 (22) International Filing Date: 9 July 1993 (09.07.93) (30) Priority data: 92112295.8 18 July 1992 (18.07.92) EP <i>(34) Countries for which the regional or international application was filed:</i> 93105298.9 30 March 1993 (30.03.93) AT et al. EP <i>(34) Countries for which the regional or international application was filed:</i> AT et al. (71) Applicant: OPPERBAS HOLDING B.V. [NL/NL]; Hoek-enrode 6-8, NL-1102 BR Amsterdam Zuidoost (NL).	(72) Inventor: BARNEA, Efrach ; 21 Halechi St., Bnei Brak, 51 200 Tel Aviv (IL). (74) Agents: MEYERS, Hans-Wilhelm et al.; Deichmannhaus am Hauptbahnhof, D-50667 Köln (DE). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: A TWO COMPONENT FIBRIN-GLUE COMPOSITION FOR IMPROVING IN VITRO FERTILIZATION (57) Abstract A two component fibrin-glue composition comprising the components A and B, wherein component A comprises fibrinogen and a protease inhibitor, component B comprises a proteolytic enzyme being capable of cleaving specifically fibrinogen and causing formation of the fibrin polymer and additionally ingredients for culturing embryonic cells of mammals in one or both of the components A and B.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CC	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

"A two component fibrin-glue composition
for improving in vitro fertilization

This invention relates to a two component fibrin-glue composition comprising the components A and B for improving in vitro fertilization.

In 1987 the first in vitro fertilization (IVF) baby was born in England. Thereafter, the in vitro fertilization became widely used throughout the world. Indications for in vitro fertilization include virtually any form of infertility.

Since the introduction of IVF the techniques have improved in all aspects of this method, for example, induction of ovulation, ovum recovery and so on except in one field where are still severe problems and complications which is the field of implantation of the embryo into the uterus. The incidence of implantation of the embryo inside the uterus is still 8 to 9 % per embryo or 20 to 30 % rate of pregnancies (since 3 to 4 embryos are normally transferred in each in vitro fertilization). It can be assumed that the transfer of young embryos (2 to 8 cells) to the uterus may play an important role in this failure to get higher rate of implantations. These embryos are not mature enough for

- 2 -

implantation at this stage. On the other hand culturing the embryos outside the uterus for longer time is damaging the embryos and only about 30 % of them will develop to the blastocyte stadium which is the developmental stage at which normal implantation occurs. Attempts for improvement of the implantation using a fibrin-glue known in the art failed. The idea was to attach the embryo with this fibrin-glue on the walls of the uterus (endometrium).

It is an object of this invention to provide a composition and a method for improving in vitro fertilization.

According to the invention the above mentioned problem can be solved with a two component fibrin-glue composition comprising components A and B wherein

- component A comprises fibrinogen and a protease inhibitor,
- component B comprises a proteolytic enzyme being capable of cleaving specifically fibrinogen and causing formation of the fibrin polymer and
- additionally ingredients for culturing embryonic cells of mammals in one or both of the components A and B.

Preferably, cryoprecipitate of whole blood or plasma is used as fibrinogen containing fraction of component A. Although, commercially available cryoprecipitate can be used. It can be advantageous to concentrate the cryoprecipitate between a factor 2 and 5.

Preferably, the cryoprecipitate is virus inactivated. A procedure for virus inactivation is, for example, described in PCT/EP 91/00503. The basic principle of this method is the treatment of the cryoprecipitate with special detergents and removing the detergent later on from the cryoprecipitate.

Preferably, the protease inhibitor present in component A is aprotinin and present in concentrations up to 10,000 U/ml based on total volume of component A. Aprotinin is commercially available under the trademark Trasylol^R or Antagosan^R. Also tranexamic acid [4-(aminomethyl)cyclohexane carboxylic acid] or its acceptable salts is a suitable agent which can be used instead of aprotinin or in combination with.

The second component B of the two component fibrin-glue composition of the invention is prepared by solution of proteolytic enzyme being capable of cleaving specifically fibrinogen. Preferably, thrombin has been used which was isolated from plasma of human beings or mammals such as bovine. The thrombin can be delivered in a lyophilized form. The reconstitution of thrombin occurs with a solution containing calcium chloride. The concentration of the protease specifically for the cleavage of fibrinogen depends on the method of transferring the embryo into the uterus. Basically, if a slow working two component fibrin-glue composition is desired the concentration of thrombin should be lower whereas if a fast working fibrin glue is desirable the concentration of thrombin should be higher (fast fibrin-glue). Typically the concentration range of thrombin is 0.4 to 4 units/ml in a slow working fibrin-glue.

Another preferred embodiment of the fibrin-glue of the present invention comprises as component B a proteolytic enzyme which is isolated from snake venom. The snake venom enzyme batroxobin which can be isolated from the south american pit viper *Bothrops mouroi* can be used. Chemically this venom is a single chain glyco peptide with a molecular weight of approximately 36,000. It is known under the name Defibrase^R which causes cleavage of the ala-16-arg/17 glue bond in fibrinogen which causes the release of fibrinopeptide A and the formation of monomeric fibrin I.

- 4 -

The use of any venom converting fibrinogen to fibrin such as Defibrase or Reptilase is preferred when the cryoprecipitate is made from autologous source and the use of the venom will avoid the use of human blood product.

According to the invention there must be present ingredients for culturing embryonic cells of mammals in the fibrin-glue of the invention. This can be achieved either by admixing the ingredients into one or both of the components A and B of the invention or dissolve these ingredients in a liquid and mixing this liquid to one or both of components A and B. Preferred ingredients for culturing embryonic cells of mammals are those comprising calcium chloride, potassium chloride, magnesium sulfate, sodium chloride, sodium bicarbonate, sodium dihydrogenphosphate, D-glucose as well as phenol. Preferably, the solution has a pH of about 7.2. It can be advantageous to add additionally pyruvic acid and antibiotics, e. g. gentamycin.

A typical procedure for preparing component A in a virus free preparation is suggested in PCT/EP 91/01850.

In a typical procedure the cryoprecipitate and the thrombin is dissolved in the medium for culturing the embryo. Of course, both components are separated in order to prevent starting of the clot reaction. The composition of two preferred culture mediums are given below. The first one is the so-called EBSS which is commercially available from Gibco Ltd. EBSS is the abbreviation for Earle's Balanced Salt Solutions. It can be purchased in liquid or powder form. The liquid contains anhydrous calcium chloride in amounts of 0.2 g/l, potassium chloride 0.4 g/l, $\text{MgSO}_4 \times 7 \text{H}_2\text{O}$ 0.2 g/l, sodium chloride 6.8 g/l, sodium bicarbonate 2.2 g/l, $\text{NaH}_2\text{PO}_4 \times 2\text{H}_2\text{O}$ 0.158 g/l and additionally D-glucose 1.0 g/l and phenol red 0.01 g/l. The respective powder form contains after being dissolved in one liter 0.20 g/L calcium chloride anhydrous, 0.4 g/l sodium chloride, 0.0977 g/l magnesium

- 5 -

sulfate anhydrous, sodium chloride 6.80 g/l, $\text{NaH}_2\text{PO}_4 \times \text{H}_2\text{O}$ and the same D-glucose and phenol red content as in the liquid form. It can be advantageous to add pyruvic acid preferably in amounts of 0.015 g/l and gentamycin in amounts of 50 mg/l.

Depending on the field where the in vitro fertilization is carried out the medium can be modified in order to meet the special requirements which may differ, for example, with respect with agricultural applications such as breeding. The above mentioned culture medium can be used also in human in vitro fertilization.

The advantage of the present fibrin-glue over the known fibrin-glue products having failed to improve the outcome of in vitro fertilization may be due to its increased anti-fibrinolytic activity preventing or postponing the embryo from one hand in the uterus on the other hand to degenerate the clot. The two component fibrin-glue composition of the present invention enables the embryo to survive in the environment of the uterus before it is lodged and permanently fixed to the uterus wall. The surviving is supported by the medium containing ingredients for embryo cell culturing. Surprisingly, the high amounts of protease inhibitor like aprotinin do not interfere with the embryo but prevent the digest of the glue. Moreover, in another preferred embodiment of the present invention the two component fibrin-glue composition is iso-osmolar. Therefore, the disadvantage of the glues of the prior art being hyper-osmolar is prevented. Hyper-osmolarity causes the death of the embryo by drying out phenomena.

The advantageous features of the fibrin-glue of the invention are the presence of salts and nutrients which are important for in vitro growing of the embryo, it contains anti-fibrinolytic activity to postpone the early degradation of the glue either by embryo or by the uterus. Moreover, the

- 6 -

antifibrinolytic potency of the embryo has to be balanced to the extent that it will enable the fetus to lyse a certain area around itself creating a halo like shape of fluid surrounded by the fibrin-glue.

Under certain circumstances it could be recommendable to include a growth factor that will enhance and speed up the maturation of the fetus.

The use of cryoprecipitate as a source of fibrinogen rather than a fibrinogen concentrate is advantageous since the former one contains ingredients like fibronectin, von Willebrand factor etc. which may be important for adhesion. Moreover, a cryoprecipitate may also contain other agents such as proteins or low molecular substances which support the development and lodging of the embryo. Also compounds having wound healing properties such as hyaluronic acid can be used.

For preparing the two component fibrin-glue composition of the invention (as it can be used in the experiments as described above) cryoprecipitate is dissolved in culture medium as described above. Then aprotinin or tranexamic acid is added to the cryoprecipitate. The concentration of aprotinin in the cryoprecipitate containing component A is preferably in the range of 6,000 to 10,000 u/ml. The concentration of tranexamic acid is preferably 10 - 200 µg/ml (final concentration). This is equivalent to an aprotinin activity of about 3,000 to 10,000 KIU/ml. The final concentration of aprotinin in the mixture of component A and B is lower because of the dilution when component B is added. The dilution factor depends on the amount of component B which is added. The concentration of fibrinogen in the cryoprecipitate solution is relatively low compared with other fibrin-glues since there is no need for strong tensile strength. Preferred are concentrations of fibrinogen in the range of 5 to 20 g/l.

- 7 -

The embryo is injected for example via the following method. The embryo is placed in the reconstituted cryoprecipitate solution in a culture dish. Then thrombin is added in concentrations of 0.4 to 4 units. The thrombin concentration determines the clotting time of the glue. the embryo is sucked in the culture fluid and injected into the uterus.

C l a i m s

1. A two component fibrin-glue composition comprising the components A and B wherein
 - component A comprises fibrinogen and a protease inhibitor,
 - component B comprises a proteolytic enzyme being capable of cleaving specifically fibrinogen and causing formation of the fibrin polymer and
 - additionally ingredients for culturing embryonic cells of mammals in one or both of the components A and B.
2. The composition of claim 1 wherein the fibrinogen containing a fraction of component A is cryoprecipitate of whole blood.
3. The composition of claims 1 and/or 2 wherein the protease inhibitor of component A is aprotinin in amounts up to 10,000 u/ml based on total volume of component A and/or 4-(aminomethyl)cyclohexane carboxylic acid or its pharmaceutically acceptable salts.
4. The composition of any one of the claims 1 to 3 wherein the proteolytic enzyme of component B is thrombin or a proteolytic enzyme derived from snake venom such as batroxobin isolated from venom of the south american pit viper Bothrops mouroi.
5. The composition of any one of the claims 1 to 4 wherein component A is virus inactivated cryoprecipitate.

- 9 -

6. The composition of any one of the claims 1 to 5 wherein the culture medium for growing embryonic cells contains calcium chloride, potassium chloride, magnesium sulfate, sodium chloride, sodium bicarbonate, sodium dihydrogenphosphate, D-glucose as well as phenol red at a pH of about 7.2 and containing optionally pyruvic acid and/or gentamycin.
7. The composition of any one of the claims 1 to 6 having an agent with wound healing such as hyaluronic acid.
8. Method of improving the success of in vitro fertilization by attaching an embryo to the endometrium whereby the embryo is transferred together with the two component fibrin-glue composition of any one of the claims 1 to 6 into the uterus.
9. Method according to claim 8 for in vitro fertilization in breeding of livestock or cattle breeding.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/01797

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61L25/00; A61K35/54		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61L ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 339 607 (S. ITAY) 2 November 1989 see column 4, line 15 - line 52; claims 1,4; examples 1-4	1-3
P,X	WO,A,9 222 312 (WADSTRÖM J.) 23 December 1992 see page 1, line 37 - line 40 see page 3, line 34 - line 39 see page 4, line 1 - line 10 see page 7, line 1 - line 17 see page 9, line 14 - line 20; examples 1-5	1-3,7
P,A	WO,A,9 215 341 (PENTAPHARM) 17 September 1992 see claims 1-3,10	4
-/--		
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
06 OCTOBER 1993		10. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		PELTRE CHR.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	GB,A,2 102 811 (IMMUNO) 9 February 1983 see page 1, line 45 - line 55; examples 1-4 -----	1-3

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9301797
SA 76739

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 06/10/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0339607	02-11-89	US-A- 5053050	01-10-91
		US-A- 4904259	27-02-90
		AU-B- 625913	16-07-92
		AU-A- 3380889	02-11-89
		DE-U- 6890480	25-03-93
		JP-A- 2209811	21-08-90

WO-A-9222312	23-12-92	AU-A- 2149192	12-01-93

WO-A-9215341	17-09-92	CH-A- 681693	14-05-93
		AU-A- 1251592	06-10-92

GB-A-2102811	09-02-83	AT-A- 369990	25-02-83
		BE-A- 893851	16-11-82
		CA-A- 1168982	12-06-84
		CH-B- 659187	15-01-87
		DE-A, C 3225102	17-02-83
		FR-A, B 2510408	04-02-83
		JP-A- 58026821	17-02-83
		NL-A- 8202982	16-02-83
		SE-B- 459848	14-08-89
		SE-A- 8204064	01-07-82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.